Efficacy and safety of casirivimab-imdevimab combination on COVID-19 patients: A systematic review and meta-analysis randomized controlled trial

{ 'indexed': { 'date-parts': [[2023, 11, 28]], 'date-time': '2023-11-28T00:50:54Z', 'timestamp': 1701132654658}, 'reference-count': 42, 'publisher': 'Elsevier BV', 'license': [ { 'start': { 'date-parts': [[2023, 11, 1]], 'date-time': '2023-11-01T00:00:00Z', 'timestamp': 1698796800000}, 'content-version': 'tdm', 'delay-in-days': 0, 'URL': 'https://www.elsevier.com/tdm/userlicense/1.0/'}, { 'start': { 'date-parts': [[2023, 11, 21]], 'date-time': '2023-11-21T00:00:00Z', 'timestamp': 1700524800000}, 'content-version': 'vor', 'delay-in-days': 20, 'URL': 'http://creativecommons.org/licenses/by-nc-nd/4.0/'}], 'content-domain': { 'domain': ['cell.com', 'elsevier.com', 'sciencedirect.com'], 'crossmark-restriction': True}, 'published-print': {'date-parts': [[2023, 11]]}, 'DOI': '10.1016/j.heliyon.2023.e22839', 'type': 'journal-article', 'created': { 'date-parts': [[2023, 11, 27]], 'date-time': '2023-11-27T18:11:59Z', 'timestamp': 1701108719000}, 'page': 'e22839', 'update-policy': 'http://dx.doi.org/10.1016/elsevier_cm_policy', 'source': 'Crossref', 'is-referenced-by-count': 0, 'title': 'Efficacy and safety of casirivimab-imdevimab combination on COVID-19 patients: A systematic ' 'review and meta-analysis randomized controlled trial', 'prefix': '10.1016', 'author': [ { 'ORCID': 'http://orcid.org/0000-0003-3793-5988', 'authenticated-orcid': False, 'given': 'Imam Adi', 'family': 'Wicaksono', 'sequence': 'first', 'affiliation': []}, { 'ORCID': 'http://orcid.org/0000-0001-7746-3271', 'authenticated-orcid': False, 'given': 'Cecep', 'family': 'Suhandi', 'sequence': 'additional', 'affiliation': []}, { 'ORCID': 'http://orcid.org/0000-0001-9555-1814', 'authenticated-orcid': False, 'given': 'Khaled M.', 'family': 'Elamin', 'sequence': 'additional', 'affiliation': []}, { 'ORCID': 'http://orcid.org/0000-0002-5985-6909', 'authenticated-orcid': False, 'given': 'Nasrul', 'family': 'Wathoni', 'sequence': 'additional', 'affiliation': []}], 'member': '78', 'reference': [ { 'key': '10.1016/j.heliyon.2023.e22839_bib1', 'article-title': 'Antiviral combination clinically better than standard therapy in severe ' 'but not in non-severe covid-19', 'volume': '13', 'author': 'Panda', 'year': '2021', 'journal-title': 'Clin. Pharmacol.'}, { 'key': '10.1016/j.heliyon.2023.e22839_bib2', 'article-title': 'Antiviral agents for the treatment of COVID-19: progress and challenges', 'volume': '3', 'author': 'Singh', 'year': '2022', 'journal-title': 'Cell Rep Med'}, { 'key': '10.1016/j.heliyon.2023.e22839_bib3', 'doi-asserted-by': 'crossref', 'DOI': '10.1016/j.ijantimicag.2023.106870', 'article-title': 'Efficacy and safety of molnupiravir treatment for COVID-19: a ' 'systematic review and meta-analysis of randomized controlled trials', 'volume': '62', 'author': 'Tian', 'year': '2023', 'journal-title': 'Int. J. Antimicrob. Agents'}, { 'key': '10.1016/j.heliyon.2023.e22839_bib4', 'doi-asserted-by': 'crossref', 'article-title': 'Efficacy of molnupiravir for the treatment of mild or moderate COVID-19 ' 'in adults: a meta-analysis', 'author': 'Benaicha', 'year': '2023', 'journal-title': 'Cureus', 'DOI': '10.7759/cureus.38586'}, { 'key': '10.1016/j.heliyon.2023.e22839_bib5', 'doi-asserted-by': 'crossref', 'DOI': '10.1038/s41467-020-20542-0', 'article-title': 'Mechanism of SARS-CoV-2 polymerase stalling by remdesivir', 'volume': '12', 'author': 'Kokic', 'year': '2021', 'journal-title': 'Nat. Commun.'}, { 'key': '10.1016/j.heliyon.2023.e22839_bib6', 'doi-asserted-by': 'crossref', 'DOI': '10.1007/s15010-021-01671-0', 'article-title': 'Efficacy and safety of remdesivir in hospitalised COVID-19 patients: a ' 'systematic review and meta-analysis', 'volume': '50', 'author': 'Angamo', 'year': '2022', 'journal-title': 'Infection'}, { 'key': '10.1016/j.heliyon.2023.e22839_bib7', 'article-title': 'Effectiveness of Paxlovid, an oral antiviral drug, against the omicron ' 'BA.5 variant in Korea: severe progression and death between July and ' 'November 2022', 'volume': '38', 'author': 'Kim', 'year': '2023', 'journal-title': 'J. Kor. Med. Sci.'}, { 'key': '10.1016/j.heliyon.2023.e22839_bib8', 'volume': '76', 'author': 'Najjar-Debbiny', 'year': '2023'}, { 'key': '10.1016/j.heliyon.2023.e22839_bib9', 'doi-asserted-by': 'crossref', 'DOI': '10.1111/bcp.15783', 'article-title': 'Post-marketing safety concerns with nirmatrelvir: a disproportionality ' 'analysis of spontaneous reports submitted to the FDA Adverse Event ' 'Reporting System', 'volume': '89', 'author': 'Zhuang', 'year': '2023', 'journal-title': 'Br. J. Clin. Pharmacol.'}, { 'key': '10.1016/j.heliyon.2023.e22839_bib10', 'doi-asserted-by': 'crossref', 'DOI': '10.1016/j.jpha.2022.10.005', 'article-title': 'Advances and challenges in using nirmatrelvir and its derivatives ' 'against SARS-CoV-2 infection', 'volume': '13', 'author': 'Chen', 'year': '2023', 'journal-title': 'J Pharm Anal'}, { 'key': '10.1016/j.heliyon.2023.e22839_bib11', 'doi-asserted-by': 'crossref', 'DOI': '10.1002/em.22510', 'article-title': 'Evaluation of the mutagenic effects of Molnupiravir and ' 'N4-hydroxycytidine in bacterial and mammalian cells by HiFi sequencing', 'volume': '63', 'author': 'Miranda', 'year': '2022', 'journal-title': 'Environ. Mol. Mutagen.'}, { 'key': '10.1016/j.heliyon.2023.e22839_bib12', 'doi-asserted-by': 'crossref', 'DOI': '10.3390/pathogens11101121', 'article-title': 'Molnupiravir as an early treatment for COVID-19: a real life study', 'volume': '11', 'author': 'Pontolillo', 'year': '2022', 'journal-title': 'Pathogens'}, { 'key': '10.1016/j.heliyon.2023.e22839_bib13', 'doi-asserted-by': 'crossref', 'DOI': '10.1016/j.biopha.2020.110532', 'article-title': 'Safety profile of the antiviral drug remdesivir: an update', 'volume': '130', 'author': 'Fan', 'year': '2020', 'journal-title': 'Biomed. Pharmacother.'}, { 'key': '10.1016/j.heliyon.2023.e22839_bib14', 'first-page': '369', 'article-title': 'Studies in humanized mice and convalescent humans yield a SARS-CoV-2 ' 'antibody cocktail', 'volume': '1979', 'author': 'Hansen', 'year': '2020', 'journal-title': 'Science'}, { 'key': '10.1016/j.heliyon.2023.e22839_bib15', 'doi-asserted-by': 'crossref', 'DOI': '10.3390/life12111758', 'article-title': 'A comprehensive review on the efficacy of several pharmacologic agents ' 'for the treatment of COVID-19', 'volume': '12', 'author': 'Haddad', 'year': '2022', 'journal-title': 'Life'}, { 'key': '10.1016/j.heliyon.2023.e22839_bib16', 'doi-asserted-by': 'crossref', 'DOI': '10.1016/j.eclinm.2021.101102', 'article-title': 'Casirivimab–Imdevimab treatment is associated with reduced rates of ' 'hospitalization among high-risk patients with mild to moderate ' 'coronavirus disease-19', 'volume': '40', 'author': 'Razonable', 'year': '2021', 'journal-title': 'EClinicalMedicine'}, { 'key': '10.1016/j.heliyon.2023.e22839_bib17', 'doi-asserted-by': 'crossref', 'DOI': '10.1056/NEJMoa2035002', 'article-title': 'REGN-COV2, a neutralizing antibody cocktail, in outpatients with ' 'covid-19', 'volume': '384', 'author': 'Weinreich', 'year': '2021', 'journal-title': 'N. Engl. J. Med.'}, { 'key': '10.1016/j.heliyon.2023.e22839_bib18', 'doi-asserted-by': 'crossref', 'DOI': '10.1136/bmj.d5928', 'article-title': "The Cochrane Collaboration's tool for assessing risk of bias in " 'randomised trials', 'volume': '343', 'author': 'Higgins', 'year': '2011', 'journal-title': 'Br. Med. J.'}, { 'key': '10.1016/j.heliyon.2023.e22839_bib19', 'doi-asserted-by': 'crossref', 'article-title': 'Effectiveness of mesenchymal stem cell secretome on wound healing: a ' 'systematic review and meta-analysis', 'author': 'Suhandi', 'year': '2023', 'journal-title': 'Tissue Eng Regen Med', 'DOI': '10.1007/s13770-023-00570-9'}, { 'key': '10.1016/j.heliyon.2023.e22839_bib20', 'volume': '20', 'author': 'Moher', 'year': '2016'}, { 'key': '10.1016/j.heliyon.2023.e22839_bib21', 'series-title': 'Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0', 'author': 'G.S', 'year': '2011'}, { 'key': '10.1016/j.heliyon.2023.e22839_bib22', 'doi-asserted-by': 'crossref', 'DOI': '10.1002/sim.1186', 'article-title': 'Quantifying heterogeneity in a meta-analysis', 'volume': '21', 'author': 'Higgins', 'year': '2002', 'journal-title': 'Stat. Med.'}, { 'key': '10.1016/j.heliyon.2023.e22839_bib23', 'doi-asserted-by': 'crossref', 'first-page': '1444', 'DOI': '10.1016/S1473-3099(22)00416-9', 'article-title': 'Efficacy and safety of a single dose of casirivimab and imdevimab for ' 'the prevention of COVID-19 over an 8-month period: a randomised, ' 'double-blind, placebo-controlled trial', 'volume': '22', 'author': 'Herman', 'year': '2022', 'journal-title': 'Lancet Infect. Dis.'}, { 'key': '10.1016/j.heliyon.2023.e22839_bib24', 'article-title': 'Casirivimab and imdevimab in patients admitted to hospital with ' 'COVID-19 (RECOVERY): a randomised, controlled, open-label, platform ' 'trial', 'volume': '399', 'author': 'Abani', 'year': '2022', 'journal-title': 'Lancet'}, { 'key': '10.1016/j.heliyon.2023.e22839_bib25', 'doi-asserted-by': 'crossref', 'DOI': '10.1016/j.ijid.2022.06.045', 'article-title': 'Repeat subcutaneous administration of casirivimab and imdevimab in ' 'adults is well-tolerated and prevents the occurrence of COVID-19', 'volume': '122', 'author': 'Isa', 'year': '2022', 'journal-title': 'Int. J. Infect. Dis.'}, { 'key': '10.1016/j.heliyon.2023.e22839_bib26', 'article-title': 'Effect of subcutaneous casirivimab and imdevimab antibody combination ' 'vs placebo on development of symptomatic COVID-19 in early asymptomatic ' 'SARS-CoV-2 infection: a randomized clinical trial', 'volume': '327', 'author': "O'Brien", 'year': '2022', 'journal-title': 'JAMA'}, { 'key': '10.1016/j.heliyon.2023.e22839_bib27', 'doi-asserted-by': 'crossref', 'article-title': 'Virologic efficacy of casirivimab and imdevimab COVID-19 antibody ' 'combination in outpatients with SARS-CoV-2 infection: a phase 2 ' 'dose-ranging randomized clinical trial', 'author': 'Portal-Celhay', 'year': '2022', 'journal-title': 'JAMA Netw. Open', 'DOI': '10.1001/jamanetworkopen.2022.25411'}, { 'key': '10.1016/j.heliyon.2023.e22839_bib28', 'doi-asserted-by': 'crossref', 'first-page': '23', 'DOI': '10.1093/infdis/jiac320', 'article-title': 'Casirivimab and imdevimab for the treatment of hospitalized patients ' 'with COVID-19', 'volume': '227', 'author': 'Somersan-Karakaya', 'year': '2022', 'journal-title': 'J. Infect. Dis.'}, { 'key': '10.1016/j.heliyon.2023.e22839_bib29', 'doi-asserted-by': 'crossref', 'DOI': '10.1056/NEJMoa2108163', 'article-title': 'REGEN-COV antibody combination and outcomes in outpatients with ' 'covid-19', 'volume': '385', 'author': 'Weinreich', 'year': '2021', 'journal-title': 'N. Engl. J. Med.'}, { 'key': '10.1016/j.heliyon.2023.e22839_bib30', 'doi-asserted-by': 'crossref', 'DOI': '10.1016/j.amjmed.2022.06.019', 'article-title': 'Beneficial and harmful effects of monoclonal antibodies for the ' 'treatment and prophylaxis of COVID-19: systematic review and ' 'meta-analysis', 'volume': '135', 'author': 'Hernandez', 'year': '2022', 'journal-title': 'Am. J. Med.'}, { 'key': '10.1016/j.heliyon.2023.e22839_bib31', 'doi-asserted-by': 'crossref', 'DOI': '10.1002/jmv.27623', 'article-title': 'The impact of neutralizing monoclonal antibodies on the outcomes of ' 'COVID-19 outpatients: a systematic review and meta-analysis of ' 'randomized controlled trials', 'volume': '94', 'author': 'Lin', 'year': '2022', 'journal-title': 'J. Med. Virol.'}, { 'key': '10.1016/j.heliyon.2023.e22839_bib32', 'first-page': '62', 'article-title': 'An eua for casirivimab and imdevimab for COVID-19', 'year': '2020', 'journal-title': 'Med. Lett. Drugs Ther.'}, { 'key': '10.1016/j.heliyon.2023.e22839_bib33', 'doi-asserted-by': 'crossref', 'first-page': '21', 'DOI': '10.1007/s15010-022-01825-8', 'article-title': 'Differential efficacy and safety of anti-SARS-CoV-2 antibody therapies ' 'for the management of COVID-19: a systematic review and network ' 'meta-analysis', 'volume': '51', 'author': 'Deng', 'year': '2023', 'journal-title': 'Infection'}, { 'key': '10.1016/j.heliyon.2023.e22839_bib34', 'doi-asserted-by': 'crossref', 'DOI': '10.3390/ph14121272', 'article-title': 'Monoclonal antibodies against sars-cov-2: current scenario and future ' 'perspectives', 'volume': '14', 'author': 'Quiros-Roldan', 'year': '2021', 'journal-title': 'Pharmaceuticals'}, { 'key': '10.1016/j.heliyon.2023.e22839_bib35', 'series-title': 'Fact Sheet for Health Care Providers: Emergency Use Authorization (EUA) ' 'of REGEN-COV (Casirivimab and Imdevimab)', 'author': 'Food and Drug Administration', 'year': '2023'}, { 'key': '10.1016/j.heliyon.2023.e22839_bib36', 'series-title': 'Casirivimab/Imdevimab: First Approval', 'author': 'Deeks', 'year': '2021'}, { 'key': '10.1016/j.heliyon.2023.e22839_bib37', 'doi-asserted-by': 'crossref', 'DOI': '10.1007/s12223-022-01001-3', 'article-title': 'Delta variant (B.1.617.2) of SARS-CoV-2: current understanding of ' 'infection, transmission, immune escape, and mutational landscape', 'volume': '68', 'author': 'Bhattacharya', 'year': '2023', 'journal-title': 'Folia Microbiol.'}, { 'key': '10.1016/j.heliyon.2023.e22839_bib38', 'article-title': 'Outcomes of monoclonal antibody infusion treatment during delta ' '(B.1.617.2) and omicron (B.1.1.529) COVID 19 variant surges among ' 'vaccinated and unvaccinated patients', 'volume': '15', 'author': 'Ghazanfar', 'year': '2022', 'journal-title': 'Health Serv. Insights'}, { 'key': '10.1016/j.heliyon.2023.e22839_bib39', 'doi-asserted-by': 'crossref', 'DOI': '10.1001/jamanetworkopen.2022.20957', 'article-title': 'Effectiveness of casirivimab-imdevimab and sotrovimab during a ' 'SARS-CoV-2 delta variant surge', 'volume': '5', 'author': 'Huang', 'year': '2022', 'journal-title': 'JAMA Netw. Open'}, { 'key': '10.1016/j.heliyon.2023.e22839_bib40', 'article-title': 'Cost-effectiveness of casirivimab/imdevimab in patients with COVID-19 ' 'in the ambulatory setting', 'volume': '28', 'author': 'Jovanoski', 'year': '2022', 'journal-title': 'J Manag Care Spec Pharm'}, { 'key': '10.1016/j.heliyon.2023.e22839_bib41', 'doi-asserted-by': 'crossref', 'DOI': '10.1371/journal.pone.0279022', 'article-title': 'Casirivimab and imdevimab: cost-effectiveness analysis of the treatment ' 'based on monoclonal antibodies on outpatients with Covid-19', 'volume': '18', 'author': 'Ruggeri', 'year': '2023', 'journal-title': 'PLoS One'}, { 'key': '10.1016/j.heliyon.2023.e22839_bib42', 'doi-asserted-by': 'crossref', 'DOI': '10.1001/jamanetworkopen.2023.21985', 'article-title': 'Health outcomes and cost-effectiveness of monoclonal SARS-CoV-2 ' 'antibodies as pre-exposure prophylaxis', 'volume': '6', 'author': 'Popping', 'year': '2023', 'journal-title': 'JAMA Netw. Open'}], 'container-title': 'Heliyon', 'original-title': [], 'language': 'en', 'link': [ { 'URL': 'https://api.elsevier.com/content/article/PII:S2405844023100478?httpAccept=text/xml', 'content-type': 'text/xml', 'content-version': 'vor', 'intended-application': 'text-mining'}, { 'URL': 'https://api.elsevier.com/content/article/PII:S2405844023100478?httpAccept=text/plain', 'content-type': 'text/plain', 'content-version': 'vor', 'intended-application': 'text-mining'}], 'deposited': { 'date-parts': [[2023, 11, 27]], 'date-time': '2023-11-27T18:12:21Z', 'timestamp': 1701108741000}, 'score': 1, 'resource': {'primary': {'URL': 'https://linkinghub.elsevier.com/retrieve/pii/S2405844023100478'}}, 'subtitle': [], 'short-title': [], 'issued': {'date-parts': [[2023, 11]]}, 'references-count': 42, 'alternative-id': ['S2405844023100478'], 'URL': 'http://dx.doi.org/10.1016/j.heliyon.2023.e22839', 'relation': {}, 'ISSN': ['2405-8440'], 'subject': ['Multidisciplinary'], 'container-title-short': 'Heliyon', 'published': {'date-parts': [[2023, 11]]}, 'assertion': [ {'value': 'Elsevier', 'name': 'publisher', 'label': 'This article is maintained by'}, { 'value': 'Efficacy and safety of casirivimab-imdevimab combination on COVID-19 patients: ' 'A systematic review and meta-analysis randomized controlled trial', 'name': 'articletitle', 'label': 'Article Title'}, {'value': 'Heliyon', 'name': 'journaltitle', 'label': 'Journal Title'}, { 'value': 'https://doi.org/10.1016/j.heliyon.2023.e22839', 'name': 'articlelink', 'label': 'CrossRef DOI link to publisher maintained version'}, {'value': 'article', 'name': 'content_type', 'label': 'Content Type'}, {'value': '© 2023 Published by Elsevier Ltd.', 'name': 'copyright', 'label': 'Copyright'}], 'article-number': 'e22839'}